Allan Bradley (Director) , Jayne V Carey (Interviewer), Samantha Barton (Interviewer)
{"title":"艾伦·布拉德利讨论了老鼠、人类和遗传学","authors":"Allan Bradley (Director) , Jayne V Carey (Interviewer), Samantha Barton (Interviewer)","doi":"10.1016/S1741-8372(04)02446-6","DOIUrl":null,"url":null,"abstract":"<div><p>Allan Bradley is one of the pioneers of embryonic stem cell technology and is world-renowned for his work on gene targeting. Allan started studying natural sciences at the University of Cambridge, UK, where he developed a strong interest for genetics. He stayed at Cambridge to complete his PhD studies and continued his post-doctorate research into mouse embryonic stem cells. In 1987, Allan left the UK to take up an assistant professorship position at Baylor College of Medicine, Texas, USA, and set up his own lab focusing on gene targeting. His expertise in genetics and in developing novel technologies led to his appointment as a Director of the Sanger Institute in 2000. Allan is an author of over 180 scientific publications, including his first paper on the creation of germline chimeras at the age of 24. Recently, Allan has been appointed as a Fellow of the Royal Society and Fellow of the Academy of Medical Sciences.</p></div>","PeriodicalId":100382,"journal":{"name":"Drug Discovery Today: TARGETS","volume":"3 4","pages":"Pages 130-133"},"PeriodicalIF":0.0000,"publicationDate":"2004-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1741-8372(04)02446-6","citationCount":"0","resultStr":"{\"title\":\"Allan Bradley discusses mice, men and genetics\",\"authors\":\"Allan Bradley (Director) , Jayne V Carey (Interviewer), Samantha Barton (Interviewer)\",\"doi\":\"10.1016/S1741-8372(04)02446-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Allan Bradley is one of the pioneers of embryonic stem cell technology and is world-renowned for his work on gene targeting. Allan started studying natural sciences at the University of Cambridge, UK, where he developed a strong interest for genetics. He stayed at Cambridge to complete his PhD studies and continued his post-doctorate research into mouse embryonic stem cells. In 1987, Allan left the UK to take up an assistant professorship position at Baylor College of Medicine, Texas, USA, and set up his own lab focusing on gene targeting. His expertise in genetics and in developing novel technologies led to his appointment as a Director of the Sanger Institute in 2000. Allan is an author of over 180 scientific publications, including his first paper on the creation of germline chimeras at the age of 24. Recently, Allan has been appointed as a Fellow of the Royal Society and Fellow of the Academy of Medical Sciences.</p></div>\",\"PeriodicalId\":100382,\"journal\":{\"name\":\"Drug Discovery Today: TARGETS\",\"volume\":\"3 4\",\"pages\":\"Pages 130-133\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2004-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/S1741-8372(04)02446-6\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug Discovery Today: TARGETS\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1741837204024466\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Discovery Today: TARGETS","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1741837204024466","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Allan Bradley is one of the pioneers of embryonic stem cell technology and is world-renowned for his work on gene targeting. Allan started studying natural sciences at the University of Cambridge, UK, where he developed a strong interest for genetics. He stayed at Cambridge to complete his PhD studies and continued his post-doctorate research into mouse embryonic stem cells. In 1987, Allan left the UK to take up an assistant professorship position at Baylor College of Medicine, Texas, USA, and set up his own lab focusing on gene targeting. His expertise in genetics and in developing novel technologies led to his appointment as a Director of the Sanger Institute in 2000. Allan is an author of over 180 scientific publications, including his first paper on the creation of germline chimeras at the age of 24. Recently, Allan has been appointed as a Fellow of the Royal Society and Fellow of the Academy of Medical Sciences.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
